Our team of experienced entrepreneurs and executives across Diagnostics, Biotech, Medical Devices, and Finance located across Switzerland, Spain, Indonesia, Singapore, Taiwan and Australia.
Senior Leadership Team
Chief Executive Office
Steven has founded / co-founded several companies including Australia’s first online stockbroker Sanford Securities in 1996, one of the world’s first mobile social networks Migme in 2003; companies in biotech, finance, mining, resources and many others.
Over the past 30 years, he is grateful to have worked with top tier venture capitalists in Silicon Valley and across the globe, with meaningful strategics (including some of the largest companies in the world), dozens of incubators and hundreds of other startups, stock exchanges and investment banks.
During this time, he has developed extensive experience in developing and commercialising compelling Internet services for the social, consumer & financial industries. He has worked professionally in chartered accounting, stockbroking, investment banking and consulting, with a wide range of financial institutions in Australia, Asia, and Europe.
Steven maintains an avid interest in a range of technologies (including IT and biotech). As a consequence of his professional experience, he has also been involved in a few hundred capital issues and transactions for over USD 1 billion, including raising over USD 100 million for companies that he has founded and led, and four exits of greater than USD 100 million each.
Steven has won numerous professional and business awards. He has extensive private and public board experience, is a frequent speaker at conferences in Silicon Valley, Europe, Asia, & Australia, and has appeared on Wall St Journal, Australian Financial Review, CNBC, Financial Times, the Economist, Bloomberg and many others.
Head of Corporate Development
David brings over 30 years’ experience as a C-suite executive including Australia’s then largest private equity firm (SBC Capital Partners), global investment banking (UBS), global manufacturing (Amcor) and industrial services businesses (Worley), and technology software businesses, with a focus on shareholder value creation. His broad sector experience includes healthcare, manufacturing, technology, and banking and finance.
He has been a strategic and corporate development advisor to world leading companies on business transformation and strategic challenges in emerging and developed markets, with a focus on profitable strategic growth. Clients have included ADM, Allnex, Amcor, AMVIG, Bayer, BTG, Campbells, Cornelius, Countrywide, Graphic Packaging International, MedHealth, NCO, Neovia, Nexans, Nine, SATS, SGH, Smith Group, Sumitomo, TGI Fridays, West Pharmaceutical, and Worley.
Previously, David led major capital raisings in Australia, Hong Kong, China, South East Asia, USA and Europe. He has led global strategic projects on every major continent and implemented numerous M&A projects worldwide. David has served as a Director and Chairman of public listed and private companies in Asia Pacific. He holds a Bachelor of Economics and Bachelor of Laws from Monash University in Australia.
Dr Michael Edel
Dr. Michael Edel completed his Science degree in Anatomy and Human Biology and Physiology at the University of Western Australia. His PhD thesis focused on mechanisms of neoplastic growth using advanced histology and molecular biology methods at the same University.
He is co-founder and director of a new spin off company Regenacellx in the field of Regenerative Medicine based in Barcelona, Spain. In response to the Covid19 pandemic Regenacellx is developing new stage technology to detect the virus that is accurate, fast and affordable.
His high level of scholarship has been recognized as Visiting Scholar at Oxford University, Department of Physiology, Anatomy and Genetics (Merton College, 2018-2019) and with awards including the French/Australia Government fellowship to study at the Institute Curie, Paris (1998), the John Nott travelling Fellowship at Harvard Medical School Boston (2000) and the DURSI fellowship at the CRG, Barcelona (2004).
He has specialized during his post-doctoral fellowships on basic cell biology and molecular genetic mechanisms of cancer (and biomarkers) and tissue regeneration, resulting in a number of high impact publications (Cell 2005, Nature Biotechnology 2008, Genes and Development 2010 and Stem Cells and Development 2012&14 and Stem Cells 2019). In 2011, he was awarded a Ramon y Cajal tenure track position scoring 93/100 and ranked top 10 researcher in Spain, awarded distinguished investigator in 2016 and currently is an ANECA accredited Associated Professor. From 2007 onwards he has held rolling national funding as Principal Investigator. His work has attracted supported by La Caxia Bank and has collaborations in industry to search for new cell based therapy applications.
ad interim CFO
Adam O’Keeffe is a senior finance specialist with over 20 years’ experience working within the business services and taxation industry. Adam has worked with leading technology & innovation businesses who specialize in areas of health sciences, technology, artificial intelligence, biotech and manufacturing. Through such work his firm has assisted in guiding and advising clients on all areas of their operations including finance, capital raising and statutory compliance.
Currently Adam operates an accounting and business services firm in Melbourne, Australia. The firm assists clients that span across various industry sectors for both listed and private companies throughout Europe, Asia, United States and Australia.
Derek Brandt brings over 25 years of international medical device and in-vitro diagnostics experience to Achiko. His professional career started in Switzerland and includes working with international organisations such as Roche and Gerresheimer, as well as with small- to mid-sized businesses in the technology and medical device industry. He successfully managed companies as CEO from the foundation to several hundred million Euro exits. Derek holds Master degrees in chemistry, statistics and pharmacokinetics.
Glenn is a 40-year global life sciences veteran, and is CEO / founder of investment and advisory firm Red Bluff Capital. He was a former CEO / COO of Ausbiotech for 13 years and has been a senior executive in multinational and Australian life sciences companies, delivering his expertise in general management, sales, marketing, finance, distribution and manufacturing. He holds several board positions including at Horizon 3 Biotech Fund, Captix Biotechnology and Endexone.
Charles brings world class international expertise with over 25 years’ experience in investment M&A, strategic partnership, startup management and ecosystem development for East Asia and Silicon Valley. He is currently Chief Investment Officer for Eastern Media Group and strategic advisor to Sigknow Biomedical, both in Taiwan. Prior he was Executive Board Member and Chief Strategy Officer at Migme, Special Assistant to Chairman and Chief Investment Officer at Foxconn, CEO at Orange Capital and Chief Financial Officer at eDynamics (acquired by Eastern Media Group). Prior he spent several years in venture capital and private equity in Greater China and Silicon Valley and he was a former investment banker at Lehman Brothers. Charles has a Bachelor of Business Administration from National Taiwan University and an MBA in Technology, Entrepreneurship and Finance from University of California, Berkeley and the Haas School of Business, graduating as a Fulbright Scholar and Haas Merit Scholar.